365 related articles for article (PubMed ID: 17091246)
1. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
Tedder TF; Baras A; Xiu Y
Springer Semin Immunopathol; 2006 Dec; 28(4):351-64. PubMed ID: 17091246
[TBL] [Abstract][Full Text] [Related]
2. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
3. [Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy].
Hamaguchi Y
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):29-34. PubMed ID: 19252375
[TBL] [Abstract][Full Text] [Related]
4. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.
Uchida J; Hamaguchi Y; Oliver JA; Ravetch JV; Poe JC; Haas KM; Tedder TF
J Exp Med; 2004 Jun; 199(12):1659-69. PubMed ID: 15210744
[TBL] [Abstract][Full Text] [Related]
5. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
[TBL] [Abstract][Full Text] [Related]
6. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.
Minard-Colin V; Xiu Y; Poe JC; Horikawa M; Magro CM; Hamaguchi Y; Haas KM; Tedder TF
Blood; 2008 Aug; 112(4):1205-13. PubMed ID: 18495955
[TBL] [Abstract][Full Text] [Related]
7. CD19: a promising B cell target for rheumatoid arthritis.
Tedder TF
Nat Rev Rheumatol; 2009 Oct; 5(10):572-7. PubMed ID: 19798033
[TBL] [Abstract][Full Text] [Related]
8. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.
Horikawa M; Minard-Colin V; Matsushita T; Tedder TF
J Clin Invest; 2011 Nov; 121(11):4268-80. PubMed ID: 22019587
[TBL] [Abstract][Full Text] [Related]
9. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
10. The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.
Lykken JM; Tedder TF
Cancer J; 2015; 21(4):351-6. PubMed ID: 26222089
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.
Yazawa N; Hamaguchi Y; Poe JC; Tedder TF
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15178-83. PubMed ID: 16217038
[TBL] [Abstract][Full Text] [Related]
12. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.
Hamaguchi Y; Uchida J; Cain DW; Venturi GM; Poe JC; Haas KM; Tedder TF
J Immunol; 2005 Apr; 174(7):4389-99. PubMed ID: 15778404
[TBL] [Abstract][Full Text] [Related]
13. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice.
Gallagher S; Turman S; Yusuf I; Akhgar A; Wu Y; Roskos LK; Herbst R; Wang Y
Int Immunopharmacol; 2016 Jul; 36():205-212. PubMed ID: 27163209
[TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
17. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
[TBL] [Abstract][Full Text] [Related]
18. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
19. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
20. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice.
Baudino L; Nimmerjahn F; Azeredo da Silveira S; Martinez-Soria E; Saito T; Carroll M; Ravetch JV; Verbeek JS; Izui S
J Immunol; 2008 Feb; 180(3):1948-53. PubMed ID: 18209093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]